Sign in
CompletedPhase 1/2

pAF for the Treatment of Osteoarthritis

Key facts

Who runs it
University of Utah
Where
Salt Lake City, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
60 people enrolled
Started
8 Jul 2021
Ended
31 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Amniotic Fluid Injection
  • Standard of Care
Record updated
27 March 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (25)Hide the full registry criteria

Who can take part

  • Patients who are between the ages of 18-70 years
  • A confirmed diagnosis of knee osteoarthritis based on clinical and radiographic findings consistent with Kellgren-Lawrence Stage 2-3 disease
  • Patients who have failed conservative treatment (e.g. steroid, activity modification, therapy, etc.) within 3 months
  • Unilateral or bilateral chronic knee joint pain >4 months
  • Patients who are able to ambulate (i.e. not wheelchair bound)
  • Patient reported a typical pain of at least 4 out of 10 during the past week using VAS numeric pain scale (0-10)
  • Patients who are of childbearing potential must agree to use adequate contraception for 90 days after study drug injection

Who cannot take part

  • Concurrent participation in another investigational trial involving systemic administration of agents (within the previous 30 days) or plans to participate in any other allogeneic stem cell therapy trial during the 12 month follow-up period
  • Any surgeries within 4 weeks, other than diagnostic surgery
  • Patients with known alcohol or drug abuse or dependence, recreational use of illicit drug or prescription medications, or have used medical marijuana within 7 days of study enrollment
  • Patients of childbearing potential who are unwilling to use adequate contraception for 90 days after study drug injection
  • Clinical suspicion of infection at injection site
  • Patients with a known allergy to local anesthetics or components of the study drug (pAF or steroid injection)
  • Patients with vascular claudication or neurologic disorders affecting the index lower limb
  • Patients with inflammatory arthropathies or connective tissue disorders; or
  • Patients with history of active cancer/malignancy within 2 years of screening, apart from adequately treated basal cell or squamous cell carcinoma of the skin not associated with the target knee
  • Subjects who have had a previous injection (i.e. steroid, platelet rich plasma, or other) within the last 3 months
  • A focal chondral defect, defined by x-ray evaluation
  • BMI >40 as defined by NIH Clinical Guidelines Body Mass Index
  • Insulin or self-reported non-insulin dependent diabetic evident of HgA1c ≥8% among known diabetics
  • Unable to consent to an English Language Consent Form
  • Frank mechanical issues (i.e. locking of the knee)
  • Workman's Compensation cases
  • Rheumatoid arthritis
  • Women who are nursing or pregnant

Where in United States

  • University of Utah Orthopedic CenterSalt Lake City, United States

About the trial

What the trial wants to find out

This is a Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis

The 2 groups in the trial

  • Amniotic Fluid InjectionTreatment being tested

    Amniotic Fluid Injection, 3ml, one time dose.

  • Standard of Care Steroid InjectionExisting treatment, for comparison

    Corticosteroids, 3ml, one time dose.

    Treatment: Standard of Care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis
Record updated
27 March 2026